Delving into the Latest Updates on AEG-33773 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Target

HSP90

Mechanism

HSP90 stimulants(Heat shock 90kDa proteins stimulants)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Chronic PainDiabetic peripheral neuropathy

Originator Organization

Aegera Therapeutics, Inc.

Active Organization-

Inactive Organization

Aegera Therapeutics, Inc.

Drug Highest PhasePendingPhase 2

First Approval Date-

Regulation-

Login to view timeline

Two Phase 1 studies have been conducted with AEG33773 and available safety and tolerability data from these studies support further clinical development of AEG33773. The current study is proposed as a proof-of-concept study to assess the potential analgesic efficacy of AEG33773 to reduce pain associated with chronic Diabetic Peripheral Neuropathy.

Start Date01 Mar 2009

Sponsor / Collaborator

Aegera Therapeutics, Inc.

100 Clinical Results associated with AEG-33773

Login to view more data

100 Translational Medicine associated with AEG-33773

Login to view more data

100 Patents (Medical) associated with AEG-33773

Login to view more data

1

Literatures (Medical) associated with AEG-33773

01 May 2010·IDrugs : the investigational drugs journal

American Society for Clinical Pharmacology and Therapeutics (ASCPT)-111th annual meeting. 17-20 March 2010, Atlanta, GA, USA.

Author: Veryard, Claire

The 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, held in Atlanta, included topics covering disclosures of new data in the field of pharmacokinetics and drug interactions. This conference report highlights selected presentations on pharmacokinetic studies of several investigational drugs, including evatanepag (Pfizer Inc), AEG-33773 (Aegera Therapeutics Inc), JNJ-16269110 (Johnson & Johnson Pharmaceutical Research & Development LLC), PF-3716539 (ViiV Healthcare), MK-0736 (Merck & Co Inc), a combination of Ginkgo biloba and cilostazol (Renexin SK Chemicals Co Ltd), PP-101 (Pacific Pharmaceuticals Co Ltd), ACT-178882 (Acetlion Ltd/Merck & Co Inc) and edoxaban (Daiichi Sankyo Co Ltd).

100 Deals associated with AEG-33773

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Pain	Phase 2	RO	Aegera Therapeutics, Inc.	01 Mar 2009
Chronic Pain	Phase 2	CA	Aegera Therapeutics, Inc.	01 Mar 2009
Chronic Pain	Phase 2	US	Aegera Therapeutics, Inc.	01 Mar 2009
Chronic Pain	Phase 2	BG	Aegera Therapeutics, Inc.	01 Mar 2009
Diabetic peripheral neuropathy	Phase 2	US	Aegera Therapeutics, Inc.	01 Mar 2009
Diabetic peripheral neuropathy	Phase 2	RO	Aegera Therapeutics, Inc.	01 Mar 2009
Diabetic peripheral neuropathy	Phase 2	BG	Aegera Therapeutics, Inc.	01 Mar 2009
Diabetic peripheral neuropathy	Phase 2	CA	Aegera Therapeutics, Inc.	01 Mar 2009